论文部分内容阅读
５８４例老年轻型缺血性卒中（ＭＩＳ）或ＴＩＡ病人随机分为阿斯匹林（ＡＳＡ）组３０１例与对照组２８３例，随访１２～６０（平均３０．２）月的结果发现：ＡＳＡ组卒中发生率与死亡发生率（１０．６％与４．３％）均低于对照组（１４．９％与７．１％），但均未达统计学差异性（Ｐ＞０．０５），ＡＳＡ组卒中与死亡危险性较对照组降低３２％〔相对危险性（ＲＲ）为０．６８，９５％可信区间为０．４６～１．０１〕；ＡＳＡ组卒中、血管性死亡及心肌梗塞发生率（２０．６％）显著低于对照组（３１．１％）（Ｐ＜０．００５），ＡＳＡ组卒中、血管性死亡及心肌梗塞危险性较对照组降低３３．８％（ＲＲ为０．６６，９５％可信区间为０．４８～０．９２）；ＡＳＡ组副作用发生率为１８．９％，严重副作用为２．７％。
584 cases of elderly patients with mild ischemic stroke (MIS) or TIA were randomly divided into aspirin (ASA) group 301 cases and control group 283 cases, followed up for 12 to 60 (average 30.2) months and found: ASA group The incidence of stroke and death (10.6% vs 4.3%) were lower than those of the control group (14.9% vs 7.1%), but the differences were not statistically significant (P> 0.05) , The risk of stroke and death in ASA group decreased by 32% (relative risk (RR) was 0.68, 95% confidence interval was 0.46 to 1.01); ASA group stroke, vascular death and myocardial The incidence of infarction (20.6%) was significantly lower than that of the control group (31.1%) (P <0.005). The risk of stroke, vascular death and myocardial infarction in the ASA group was decreased by 33.8% 0.66, 95% confidence interval was 0.48 to 0.92). The incidence of side effects in ASA group was 18.9% and the serious side effect was 2.7%.